跳至主要内容
临床试验/CTRI/2020/07/026850
CTRI/2020/07/026850尚未招募未知

Effects of metformin plus gliclazide versus metformin plus glimepiride on cardiovascular risk factors in patients with type 2 diabetes mellitus.

Dr Salman H Rizvi0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Individuals more than 18 yrs of age.
  • 2. Patients who had failed on monotherapy with metformin (1000 mg/day).
  • 3. HbA1c >= 6.5%.
  • 4. FPG >126 mg/dl (7.0 mmol/l). Fasting is defined as no caloric intake for at least 8 hours.
  • 5. PPPG >200 mg/dl (11.1 mmol/l) two hours after meals.

排除标准

  • 1. Those patients requiring change in dose as per treating physician during study period will be excluded from the study.
  • 2. Patient with renal disease.
  • 3. Patient on insulin 6 months prior to screening.
  • 4. Patients with any acute or chronic complication of diabetes mellitus.
  • 5. Patients with infection 4 wks. prior to screening.
  • 6. Patients on parenteral glucocorticoids, growth hormone.
  • 7. Patient suffering from active or chronic hepatic disease.
  • 8. Pregnant/ lactating women.

研究者

发起方
Dr Salman H Rizvi

相似试验